Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if STTK is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
25 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 2
100 filers reported a long position in STTK for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | $93.2M | 13.4M | +36.2% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $56.4M | 8.1M | +74.9% |
| Redmile Group, LLC | $47.8M | 6.9M | +24.4% |
| ORBIMED ADVISORS LLC | $43.8M | 6.3M | Unchanged |
| Prosight Management, LP | $41.3M | 6M | +19.1% |
| BlackRock, Inc. | $27.3M | 3.9M | +670.5% |
| Frazier Life Sciences Management, L.P. | $26M | 3.8M | New |
| NEXTBio Capital Management LP | $25.9M | 3.7M | +18.3% |
| Deep Track Capital, LP | $25.7M | 3.7M | New |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.3M | 3.2M | +40.9% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.